Is it safe to combine benazepril (ACE inhibitor) with metoprolol (beta‑blocker) for hypertension or heart failure, and what are the recommended dosing and monitoring guidelines?

Combining Benazepril and Metoprolol is Safe and Recommended

The combination of benazepril (ACE inhibitor) and metoprolol (beta-blocker) is safe, well-tolerated, and explicitly recommended by major guidelines for patients with hypertension, heart failure with reduced ejection fraction (HFrEF), or coronary artery disease. 1, 2, 3

Clinical Indications for Combination Therapy

Heart Failure with Reduced Ejection Fraction (LVEF <40%)

Both ACE inhibitors and beta-blockers are Class I, Level A recommendations as initial therapy for HFrEF. 2, 4 These medications should be:

• Started together (not sequentially) in patients with systolic dysfunction
• Continued indefinitely unless contraindicated
• Titrated to target doses proven effective in clinical trials 1, 5

For metoprolol specifically, use metoprolol succinate (extended-release) at:

• Starting dose: 12.5-25 mg once daily
• Target dose: 200 mg once daily 5, 6

For benazepril:

• Starting dose: 2.5 mg daily
• Maintenance dose: 10 mg twice daily (target based on enalapril equivalents) 7

Hypertension with High Cardiovascular Risk

The combination is particularly beneficial for patients with:

• Coronary artery disease (stable angina, post-MI)
• Left ventricular hypertrophy
• Diabetes mellitus
• Chronic kidney disease 1, 2, 3

Beta-blockers should be used for 3 years minimum in all patients post-MI or acute coronary syndrome, and ACE inhibitors should be continued indefinitely. 1

Coronary Artery Disease

For stable angina, beta-blockers are the preferred initial therapy, and ACE inhibitors should be added for all patients with documented CAD. 8, 9 A study specifically evaluating benazepril plus metoprolol in chronic stable angina demonstrated the combination prolonged exercise time and time to ST-segment depression more effectively than either agent alone. 10

Dosing Strategy

Initiation Sequence

1. Start with low doses of both agents simultaneously in HFrEF patients 2, 5
2. For hypertension without HF, either agent can be started first, though beta-blockers are preferred if angina is present 8

Titration Protocol

• Double doses at 2-week intervals minimum 5
• Aim for target doses from clinical trials, or the highest tolerated dose
• Monitor heart rate, blood pressure, and clinical status at each visit
• Check renal function and electrolytes 1-2 weeks after initiation and after final dose titration 2, 5

Target Doses

Metoprolol succinate: 200 mg once daily
Benazepril: 20 mg twice daily (equivalent to proven ACE inhibitor doses) 5, 7

Monitoring Requirements

Essential Parameters

• Blood pressure: Target <130/80 mmHg for most patients 3
• Heart rate: Acceptable range 55-70 bpm; if <50 bpm with symptoms, reduce beta-blocker dose 5
• Renal function: Check creatinine and potassium within 1-2 weeks of initiation 2, 11
• Potassium: Monitor for hyperkalemia, especially if using potassium-sparing diuretics or aldosterone antagonists 11

Warning Signs Requiring Dose Adjustment

• Symptomatic hypotension: Consider reducing diuretic dose first before adjusting ACE inhibitor or beta-blocker 5
• Worsening heart failure signs: Increase diuretic dose; only reduce beta-blocker if marked fatigue or severe bradycardia 5
• Serum creatinine increase >30% from baseline: Acceptable if stable; investigate if progressive 2
• Potassium >5.5 mEq/L: Reduce or stop potassium supplements, review other medications 11

Safety Considerations

Drug Interactions to Avoid

Do NOT combine with:

• Other ACE inhibitors or ARBs (dual RAS blockade increases risk of hypotension, hyperkalemia, and renal dysfunction) 3, 11
• Aliskiren (direct renin inhibitor) in patients with diabetes or GFR <60 mL/min 3, 11
• Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) with metoprolol due to bradycardia and heart block risk 3, 6

Safe Combinations

Can be combined with:

• Thiazide or loop diuretics (monitor potassium) 2, 4
• Dihydropyridine calcium channel blockers (amlodipine, felodipine) 4, 12
• Aldosterone antagonists (spironolactone, eplerenone) in HFrEF with close potassium monitoring 1, 2
• Hydralazine/isosorbide dinitrate if additional BP control needed 2, 12

Common Pitfalls

• Do not abruptly discontinue metoprolol in patients with coronary disease—risk of rebound ischemia, MI, and arrhythmias 13
• Do not withhold beta-blockers during acute HF decompensation unless severe bradycardia or cardiogenic shock; instead, optimize diuretics 5
• Do not use NSAIDs chronically with benazepril—increases risk of renal dysfunction and attenuates antihypertensive effect 11
• Benazepril may mask hypoglycemia symptoms in diabetic patients on insulin; monitor glucose closely 11

Contraindications

Benazepril:

• History of angioedema with ACE inhibitors
• Bilateral renal artery stenosis
• Pregnancy 11

Metoprolol:

• Severe bradycardia (<45 bpm)
• Second- or third-degree heart block without pacemaker
• Cardiogenic shock
• Decompensated heart failure requiring inotropic support 13

Evidence Quality

The recommendation for combining ACE inhibitors and beta-blockers in HFrEF is supported by multiple Class I, Level A evidence from landmark trials demonstrating mortality reduction 1, 2. The 2018 ACC/AHA and Canadian guidelines both strongly endorse this combination as foundational therapy 2, 3. While specific data on benazepril-metoprolol combination is limited to one small trial in stable angina 10, the class effects of ACE inhibitors and beta-blockers are well-established and generalizable across agents within each class 1, 5.